{"type":"trials","record":{"id":41496,"source_id":"clinicaltrials-gov","external_id":"NCT07640997","title":"Real-world Study of Aflibercept 8 mg in nAMD","brief_summary":"The goal of this observational study is to explore the effectiveness of aflibercept 8 mg in treating both treatment-naive and previously treated patients with neovascular age-related macular degeneration (nAMD) in a real-world setting. The main questions it aims to answer are: What are the short-term and long-term efficacy outcomes of aflibercept 8 mg in treatment-naive or previously treated nAMD patients? What are the safety characteristics and the treatment patterns of aflibercept 8 mg in these patient populations? Participants will: Receive aflibercept 8 mg as part of their clinical treatment for nAMD. Undergo assessments to evaluate both the efficacy and safety of the treatment over the short and long term. Provide data on their visual acuity (BCVA) changes at multiple follow-up points (4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months). Report any adverse events and treatment patterns during the study period. Have their central subfield thickness (CST) measured at specified intervals. This study will help inform clinical practices regarding the use of aflibercept in nAMD patients and contribute to understanding its effectiveness and safety in real-world settings.","overall_status":"Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Peking University People's Hospital","enrollment":300,"countries":["China"],"start_date":"2025-11-11","completion_date":"2027-12-31","last_update_date":"2026-06-11","source_url":"https://clinicaltrials.gov/study/NCT07640997","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Peking University People's Hospital","interventions":["Aflibercept 8mg"],"registry_source":"ClinicalTrials.gov","outcome_measures":["The change of best corrected visual acuity (BCVA) from baseline to 12 months（BCVA will be examined under real-world con…","The change of best corrected visual acuity (BCVA) from baseline to 4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months…","The change of central subfield thickness(CST) from baseline to 4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months as e…","Number of aflibercept 8 mg injections in the study eye during the first 6 months and 12 months — Baseline to Month 12","Number of visits regarding the study eye by type of visit during the 6 months and 12 months treatment period — Baseline…","The proportion of study eyes for each treatment regimen (fixed regimen, treatment-extension regimen, as-needed regimen,…","The proportion of study eyes for the distribution of the last treatment interval from baseline to 6 months and 12 month…","The number of patients who experienced (serious) adverse events and (serious) drug-related adverse events from the base…","Percentage of eyes without IRF and/or SRF in the central macular area at 4 weeks, 8 weeks, 16 weeks, 6 months, and 12 m…","Percentage of eyes with regression/or improvement of PED at 4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months after t…"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration (nAMD)","Aflibercept 8mg"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07640997","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-11-11 to 2027-12-31","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.822Z","intervention":["Aflibercept 8mg"],"participants":300,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The change of best corrected visual acuity (BCVA) from baseline to 12 months（BCVA will be examined under real-world con…","The change of best corrected visual acuity (BCVA) from baseline to 4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months…","The change of central subfield thickness(CST) from baseline to 4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months as e…","Number of aflibercept 8 mg injections in the study eye during the first 6 months and 12 months — Baseline to Month 12","Number of visits regarding the study eye by type of visit during the 6 months and 12 months treatment period — Baseline…","The proportion of study eyes for each treatment regimen (fixed regimen, treatment-extension regimen, as-needed regimen,…","The proportion of study eyes for the distribution of the last treatment interval from baseline to 6 months and 12 month…","The number of patients who experienced (serious) adverse events and (serious) drug-related adverse events from the base…","Percentage of eyes without IRF and/or SRF in the central macular area at 4 weeks, 8 weeks, 16 weeks, 6 months, and 12 m…","Percentage of eyes with regression/or improvement of PED at 4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months after t…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41496","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}